Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesRadiation OncologyAmbetter Nevada Proton Neutron Coverage Update | O…
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.MP.70

    Proton and Neutron Beam Therapies

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.MP.70 alerts

    Get alerted when Policy CP.MP.70 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and coverage criteria for proton beam therapy (PBT) and neutron beam therapy (NBT) for Ambetter Nevada members, including specific indications where PBT/NBT are considered medically necessary and a statement that other indications are not medically necessary.

    Policy Summary
    PayerAmbetter Nevada
    PolicyProton and Neutron Beam Therapies
    Policy CodePolicy CP.MP.70
    Change TypeNo material change
    Effective DateN/A
    Last ReviewNov 25, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for PBT/NBT and document that the requested indication meets the listed medical necessity criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~23
    individual listed indications for PBT
    Select salivary tumorsNBT specific use
    CEDCED referenced
    6 codesProcedure codes referenced
    ManyReferences

    Medically Necessary and Not Medically Necessary Indications

    Medically Necessary Indications for Proton Beam Therapy (PBT)

    PBT is considered medically necessary when any one of the following indications is met:

    PBT indications list: A. Ocular tumors, including but not limited to, intraocular melanomas; B. Primary spine or spinal cord tumors or metastatic tumors of the spine or spinal cord for which organ-at-risk tolerance may be exceeded with photon treatments; C. Tumors that approach or are located at the base of the skull, including but not limited to, chordoma or chondrosarcoma; D. Hepatocellular cancer and intra-hepatic biliary cancers; E. Primary or benign solid tumors or other hematologic malignancies in members/enrollees ≤ 21 years old; F. Tumors/cancers that can be treated with any other type of radiation in members/enrollees with a known genetic mutation/syndrome increasing the risk of cancer; G. Malignant and benign primary CNS tumors, excluding IDH wild-type glioblastoma (GBM); H. Pituitary neoplasms; I. Advanced staged and unresectable head and neck cancers; J. Cancers of the nasopharynx, nasal cavity, paranasal sinuses and other accessory sinuses, when normal tissue constraints cannot be met by photon-based therapy; K. Non-metastatic retroperitoneal sarcomas; L. Re-irradiation cases where cumulative critical structure dose would exceed tolerance dose; M. Primary tumors of the mediastinum, including thymic tumors (i.e. thymoma, thymic carcinoma), mediastinal tumors and mediastinal lymphomas (i.e. Hodgkin lymphoma and Non-Hodgkin lymphoma), and thoracic sarcomas; N. Non-small cell lung cancer, to spare critical structures when critical organ dose constraints cannot be met with photon therapy; O. Malignant pleural mesothelioma; P. Primary malignant or benign bone tumors; Q. Medically inoperable patients with a diagnosis of cancer typically treated with surgery where dose escalation is required due to the inability to receive surgery; R. Primary and metastatic tumors requiring craniospinal irradiation; S. Primary cancers of the esophagus; T. Advanced and unresectable pelvic tumors with significant pelvic and/or peri-aortic nodal disease; U. Members/enrollees with a single kidney or transplanted pelvic kidney with treatment of an adjacent target volume and in whom maximal avoidance of the organ is critical; V. Salivary gland tumors; W. Arteriovenous malformations (AVM).

    Full list extracted verbatim from policy sections I.A through I.W.

    Medically Necessary Indications for Neutron Beam Therapy (NBT)

    NBT is considered medically necessary for salivary gland tumors when any of the following are met:

    NBT salivary gland criteria: A. The tumor is considered surgically unresectable, recurrent, or is resected with gross residual disease or positive margins; B. Member/enrollee is medically inoperable.

    NBT limited to select salivary gland tumor scenarios per policy.

    Not Medically Necessary / Coverage with Evidence Development

    All other indications for PBT and NBT:

    Other indications: All other indications for PBT and NBT are considered not medically necessary as insufficient evidence exists to recommend proton and/or neutron beam therapy as superior to other treatments available; select unlisted indications may be considered under Coverage with Evidence Development (CED) when the member is enrolled in an IRB‑approved clinical trial or a multi‑institutional patient registry adhering to CED requirements.

    Policy directs not medically necessary stance for unlisted indications and references ASTRO CED guidance for evidence development.

    Indications that are not expressly listed in this policy as medically necessary for proton beam therapy (PBT) or neutron beam therapy (NBT) are considered not medically necessary and may be denied. The policy specifies an enumerated set of PBT indications (sections I.A–I.W) and a limited NBT indication set for salivary gland tumors; requests outside those listed indications will be adjudicated as not covered under this clinical policy.

    The NCCN previously considered neutron beam therapy promising for unresectable salivary gland cancers but now no longer recommends NBT as a general solution for these cancers because of diminishing demand, high rates of long-term toxicity, concerns about the methodological robustness of available randomized trial data, and closure of nearly all U.S. treatment centers; the panel nonetheless recognizes potential value for select patients.

    Except for the specific indications enumerated for PBT and the limited NBT salivary gland scenarios, the policy states that all other indications for PBT and NBT are considered not medically necessary due to insufficient evidence of superiority over other treatments. Some unlisted indications may be considered under a Coverage with Evidence Development (CED) paradigm when patients are enrolled in IRB‑approved clinical trials or multi‑institutional registries consistent with ASTRO and payer CED expectations.

    Procedure and Billing Codes

    Referenced coding guidancemixed
    No codes listed
    Procedure Codes referencedCPT
    77423High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s).
    77520Proton treatment delivery; simple, without compensation.
    77522Proton treatment delivery; simple, with compensation.
    77523Proton treatment delivery; intermediate.
    77525Proton treatment delivery; complex.
    S8030Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy.
    Billing Rule

    Authorization and coding — coding/coverage mismatch risk

    Inclusion or exclusion of CPT/HCPCS codes in this policy does not guarantee coverage; verify coding and coverage before claim submission.

    • Codes in the policy are provided for informational purposes and are not all‑inclusive.
    • Providers must reference the most up‑to‑date professional coding guidance prior to submitting claims.

    Authorization, Documentation, and Billing Actions for Providers

    Prior Authorization

    Prior authorization required

    Obtain prior authorization for PBT/NBT per the Health Plan; requests will be adjudicated against the policy's listed medically necessary indications and may consider Coverage with Evidence Development when applicable.

    Prior Authorization

    Obtain authorization consistent with Health Plan procedures

    Secure authorization consistent with Health Plan procedures and ensure submitted codes align with the CPT/HCPCS codes referenced in the policy when requesting coverage.

    • Policy implies prior authorization; follow plan-specific submission processes.
    • Confirm coding matches the policy's referenced procedure codes prior to submission.

    Clinical Background and Rationale

    Proton beam therapy (PBT) is an external beam radiation modality that uses positively charged particles to deliver dose with a distinct depth‑dose distribution, enabling reduction of dose to surrounding normal tissues compared with photon techniques. This property can potentially reduce toxicity and is particularly useful for tumors adjacent to critical structures or in children where sparing healthy tissue is important. Neutron beam therapy (NBT) uses neutrons, which are heavier than photons and have been studied for very dense tumors (most commonly salivary gland tumors), but NBT is less widely available and associated with greater long‑term toxicity concerns.

    Key Terms and Therapy Definitions

    Proton beam therapy (PBT) definition
    DefinitionA form of external beam radiation therapy (EBRT) that uses protons to precisely target tumor tissue, allowing deep penetration with reduced dose to surrounding healthy tissue.
    Primary clinical advantageDelivers less radiation to surrounding tissues compared with photons, which can reduce toxicity for tumors near critical structures or in children.
    Typical use casesMay be more effective for inoperable tumors or when damage to healthy tissue would pose an unacceptable risk.
    Modality classExternal beam radiation therapy using positively charged subatomic particles (protons).
    Availability noteSpecialized technology requiring proton delivery systems; not universally available at all centers.
    Neutron beam therapy (NBT) definition — clinical context
    Policy Summary
    PayerAmbetter Nevada
    PolicyProton and Neutron Beam Therapies
    Policy CodePolicy CP.MP.70
    Change TypeNo material change
    Effective DateN/A
    Last ReviewNov 25, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for PBT/NBT and document that the requested indication meets the listed medical necessity criteria.
    SourceLink
    On This Page
    Medically Necessary and Not Medically Necessary IndicationsProcedure and Billing CodesAuthorization, Documentation, and Billing Actions for ProvidersClinical Background and RationaleKey Terms and Therapy Definitions
    Step Therapy

    No step therapy specified

    This policy does not establish any required step therapy sequence for PBT or NBT.

    Note

    Provider actions — submit authorization and supporting clinical evidence

    Providers must follow the Health Plan's authorization and claims procedures for PBT/NBT requests; submit clinical documentation demonstrating the member meets one of the policy's medically necessary indications.

    Documentation Required

    Document tumor localization and treatment planning

    Include tumor localization and treatment planning records (e.g., indirect ophthalmoscopy, transillumination, ultrasound, intraoperative/postoperative imaging, and use of radio‑opaque fiducial markers for ocular tumors) and apply current CPT coding guidance in the medical record.

    • Document tumor/target definition methods used (funduscopic exam, fluorescein angiogram, ultrasound, direct intraoperative measurements).
    • If fiducial markers or scleral tantalum rings are used for localization, include operative notes and imaging confirming placement.
    Documentation Required

    Align documentation with plan rules and NCDs/LCDs

    Ensure submissions comply with Health Plan coverage terms, applicable state/federal requirements, and any relevant Medicare NCDs/LCDs; align documentation with the policy's medical necessity criteria.

    • For Medicare members, review applicable NCDs, LCDs, and Medicare Coverage Articles prior to applying policy criteria.
    • When state Medicaid provisions differ, state Medicaid rules take precedence.
    Denial Risk

    Risk of denial for non‑listed indications

    Requests for PBT or NBT for indications not listed as medically necessary in this policy are considered not medically necessary and may be denied.

    DefinitionAn external beam radiation therapy that uses neutrons (heavier than photons) to destroy tumor cells; may be more effective against very dense tumors.
    Clinical contextHistorically studied most commonly for salivary gland tumors that are unresectable, recurrent, or have gross residual disease.
    LimitationsDifficult to generate and deliver neutrons, limited clinical availability, and associated with higher long-term toxicity concerns.
    Guideline statusNCCN no longer recommends NBT as a general solution for salivary gland cancers due to diminishing demand, high long-term toxicity, concerns about randomized trial robustness, and closure of most U.S. centers, though it may have value for select patients.
    Neutron Beam Therapy (NBT) definition (alternate / duplicate)
    Alternate definitionRadiation therapy using neutrons instead of photons; neutrons are heavier and can cause greater damage to dense tumor tissue.
    Primary indications studiedMost commonly evaluated for salivary gland tumors, particularly unresectable or recurrent disease.
    Practical considerationsRarely available due to delivery challenges; most U.S. centers have closed, limiting access.
    Safety/effectiveness concernsAssociated with higher long-term toxicity and limitations in the robustness of randomized trial data supporting widespread use.